Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200-Day Moving Average – Here’s Why

Tenax Therapeutics, Inc. (NASDAQ:TENX) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $11.81 and traded as high as $13.32. Tenax Therapeutics shares last traded at $12.78, with a volume of 451,691 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TENX shares. Guggenheim lifted their target price on Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, March 16th. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Cantor Fitzgerald initiated coverage on Tenax Therapeutics in a research note on Tuesday, March 17th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Lifesci Capital raised Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.67.

Tenax Therapeutics Stock Performance

The firm has a market cap of $219.82 million, a price-to-earnings ratio of -9.61 and a beta of 1.00. The company has a 50 day moving average price of $13.80 and a 200 day moving average price of $11.81.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.88. On average, research analysts forecast that Tenax Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $151,000. Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $2,317,000. Quadrature Capital Ltd purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $252,000. Perceptive Advisors LLC purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $5,353,000. Finally, Artia Global Partners LP purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $513,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.